Pneumococcal conjugate vaccines: Proceedings from an Interactive Symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy

Stephen I. Pelton, Ron Dagan, Beverly M. Gaines, Keith P. Klugman, Dagna Laufer, Katherine O'Brien, Heinz J. Schmitt

Research output: Contribution to journalArticlepeer-review

Abstract

Globally, Streptococcus pneumoniae is a leading cause of invasive and noninvasive disease in infants and young children. The emergence of antibiotic-resistant strains has increased interest in prevention through immunization. Currently, the only available conjugate pneumococcal vaccine is a seven-valent formulation, PNCRM7. This paper presents excerpts from a symposium that provided an update of ongoing surveillance data and clinical trials evaluating pneumococcal conjugate vaccines. The topics addressed included: (1) PNCRM7 postmarketing safety data; (2) the impact of PNCRM7 in premature infants; (3) the direct and indirect effect of pneumococcal conjugate vaccines on colonization; (4) the effect of pneumococcal conjugate vaccines on replacement disease and the rate of resistance among replacement serotypes; (5) the current recommendations for the use of PNCRM7; and (6) the potential impact of conjugate vaccines in Europe and the Asia-Pacific region.

Original languageEnglish (US)
Pages (from-to)1562-1571
Number of pages10
JournalVaccine
Volume21
Issue number15
DOIs
StatePublished - Apr 2 2003

Keywords

  • Acute otitis media
  • Pneumococcal conjugate vaccines
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Pneumococcal conjugate vaccines: Proceedings from an Interactive Symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy'. Together they form a unique fingerprint.

Cite this